Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Colitis, Ulcerative 3Urogenital Neoplasms 2Inflammatory Bowel Diseases 2Crohn Disease 2Colitis 2Carcinoma, Non-Small-Cell Lung 2Takayasu Arteritis 1Recurrence 1Melanoma 1Lung Neoplasms 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Sunitinib 3Specimen Handling 3Paclitaxel 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Drug Therapy 3Carboplatin 3Biopsy 3Abiraterone Acetate 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Suspensions 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urogenital Neoplasms × CT-P13 × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡